Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated application study of BBI-4000 (sofpironium bromide) in primary axillary hyperhidrosis
jRCT2080224187Phase 1Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of sofpironium in essential axillary hyperhidrosis, sponsored by Kaken Pharmaceutical Co., Ltd. Started Dec 2018; status: completed.
02
Drugs
sofpironium
03
Conditions
essential axillary hyperhidrosis
Beyond the preview
Go deeper on jRCT2080224187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224187.